Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study

被引：0
|
作者：
Sabrina Wiebe
David Schnell
Raimund Külzer
Dietmar Gansser
Anne Weber
Gudrun Wallenstein
Atef Halabi
Anja Conrad
Sven Wind
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG,Translational Medicine and Clinical Pharmacology
[2] Datamap GmbH,undefined
[3] Clinical Research Services (CRS) Kiel GmbH,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2017年 / 42卷
关键词：
Renal Impairment; Epidermal Growth Factor Receptor Mutation; Plasma Protein Binding; Severe Renal Impairment; Advanced Solid Tumour;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：461 / 469
页数：8
相关论文
共 50 条
  • [41] Pharmacokinetics and tolerability of intravenous posaconazole in healthy Chinese volunteers: a randomized, open-label and single-dose study
    Ji, Wei
    Zhao, Hengli
    Yang, Shaomei
    Wen, Qing
    He, Kun
    PHARMAZIE, 2020, 75 (10): : 491 - 493
  • [42] Effect of age and renal impairment on the pharmacokinetics and safety of trimetazidine: An open-label multiple-dose study
    Nenchev, Nencho
    Skopek, Jiri
    Arora, Deepa
    Samad, Abdus
    Kaplan, Sigal
    Domahidy, Monika
    de Voogd, Hanka
    Boehmert, Stella
    Ramos, Rita S.
    Jain, Shashank
    DRUG DEVELOPMENT RESEARCH, 2020, 81 (05) : 564 - 572
  • [43] SINGLE-DOSE PHARMACOKINETICS OF CEFPIROME IN PATIENTS WITH RENAL IMPAIRMENT
    LAMEIRE, N
    MALERCZYK, V
    DREES, B
    LEHR, K
    ROSENKRANZ, B
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (01) : 24 - 30
  • [44] Effects of renal impairment on single-dose pharmacokinetics of entecavir
    Yan, JH
    Bifino, M
    Xie, J
    Freund, J
    Rahim, S
    Zhang, D
    Grasela, D
    LaCreta, F
    JOURNAL OF HEPATOLOGY, 2005, 42 : 195 - 195
  • [45] A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
    Bola Tayo
    Lesley Taylor
    Farhad Sahebkar
    Gilmour Morrison
    Clinical Pharmacokinetics, 2020, 59 : 747 - 755
  • [46] A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
    Tayo, Bola
    Taylor, Lesley
    Sahebkar, Farhad
    Morrison, Gilmour
    CLINICAL PHARMACOKINETICS, 2020, 59 (06) : 747 - 755
  • [47] The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies
    Tomohiro Kusawake
    Donna Kowalski
    Akitsugu Takada
    Kota Kato
    Masataka Katashima
    James J. Keirns
    Michaelene Lewand
    Kenneth C. Lasseter
    Thomas C. Marbury
    Richard A. Preston
    Advances in Therapy, 2017, 34 : 2612 - 2624
  • [48] The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies
    Kusawake, Tomohiro
    Kowalski, Donna
    Takada, Akitsugu
    Kato, Kota
    Katashima, Masataka
    Keirns, James J.
    Lewand, Michaelene
    Lasseter, Kenneth C.
    Marbury, Thomas C.
    Preston, Richard A.
    ADVANCES IN THERAPY, 2017, 34 (12) : 2612 - 2624
  • [49] Pharmacokinetics and Safety of Ezetimibe/Simvastatin Combination Tablet An Open-Label, Single-Dose Study in Healthy Chinese Subjects
    Chu, Nan-Nan
    Chen, Wei-Li
    Xu, Hong-Rong
    Li, Xue-Ning
    CLINICAL DRUG INVESTIGATION, 2012, 32 (12) : 791 - 798
  • [50] Pharmacokinetics, safety, and tolerability of sulcardine sulfate: an open-label, single-dose, randomized study in healthy Chinese subjects
    Chen, Qian
    Qian, Hong-jie
    Wang, Wei
    Zhang, Meng-qi
    Lu, Dong-ying
    Lu, Chuan
    Jin, Jie-mei
    Hu, Chao-ying
    Liu, Gang-yi
    Jia, Jing-ying
    Zheng, Hong-chao
    Li, Xue-ning
    Yu, Chen
    Wang, Yi-ping
    Liu, Yun
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 (01) : 120 - 125
12345